Purpose: To study the genetic aetiology of retinal dystrophies (RD) in Finnish patients. Methods: A targeted next-generation sequencing (NGS) panel of 105 retinal dystrophy genes was used in a cohort of 55 RD patients. Results: The overall diagnostic yield was 60% demonstrating the power of this approach. Interestingly, a missense mutation c.375C>G p.(Cys125Trp) in the CERKL gene was found in 18% of the patients in either a homozygous or compound heterozygous state. Data from Exome Aggregation Consortium (ExAC) Browser show that the CERKL c.375C>G p.(Cys125Trp) allele is enriched in the Finnish population and thus is a founder mutation. Furthermore, we report the clinical picture of 18 patients with mutations in the CERKL gene. CERKL mutations cause a macular-onset disease, in which symptoms first become apparent at the second decade. We also detected other novel founder mutations in the CERKL, EYS, RP1, ABCA4 and GUCY2D genes. Conclusion: Our report indicates that the first diagnostic test for Finnish patients with sporadic or autosomal recessive RD should be a targeted test for founder mutations in the CERKL, EYS, RP1, ABCA4 and GUCY2D genes. These results confirm the utility of NGS-based gene panels as a powerful method for mutation identification in RD, thus enabling improved genetic counselling for these families.
Introduction
Retinal dystrophies (RD) are a large group of chronic diseases causing vision loss and affecting millions of individuals worldwide. RDs are a common cause of childhood visual impairment and blindness. A recent epidemiological study showed 1:3454 prevalence of generalized retinal dystrophy in Danish population (Bertelsen et al. 2014) . Approximately 50% of the cases represent retinitis pigmentosa (RP), which is primarily caused by rod-photoreceptor degeneration, often followed by cone cell involvement. Retinitis pigmentosa (RP) causes night blindness, peripheral vision loss, retinal pigmentation and arteriolar attenuation. Cone-rod dystrophies (CRD) represent another form of RD and are characterized by primary cone involvement or, sometimes, by concomitant loss of both cones and rods. Cone-rod dystrophies (CRD) is a macular-onset disease, which initially causes reduced visual acuity (VA), and abnormalities of colour vision, central scotomas as well as photophobia, followed by rod dysfunction and loss, causing nyctalopia and progressive peripheral visual field loss. Typical RP, also called rod cone dystrophy (RCD), and CRD reflect the opposite sequence of events. The clinical course of CRD is generally more severe and rapid than that of RP, leading to earlier legal blindness and disability; however, the end stages of CRD and RP are very similar. The genetic aetiology of RD is extremely heterogeneous. To date, over 200 genes associated with autosomal dominant, autosomal recessive and X-linked recessive modes of inheritance have been identified as the cause of retinal dystrophy (RetNet, The Retinal Information Network 2013, retrieved from sph.uth.edu/retnet/). Genetic and clinical heterogeneity in RD complicates the efforts to characterize the underlying molecular defect. However, the recent advances in sequencing technologies, in particular NGS techniques, have dramatically changed the ability to identify causative mutations in this patient group, enabling improved genetic counselling for affected families (Daiger et al. 2014; Wang et al. 2014) .
The aim of this study was to analyze the genetic aetiology of RD in 55 Finnish patients using a targeted NGS-based gene panel of 105 genes implicated in RD.
Materials and methods
This study includes two sets of patients. The first set included 55 consecutive patients with a diagnosis of any retinal dystrophy without previously known molecular aetiology, referred to the Department of Clinical Genetics from the Department of Ophthalmology, between September 2012 and September 2014. Their samples were analysed with an NGS-based gene panel by the Manchester Centre for Genomic Medicine (see below). Secondly, additional six unrelated patients diagnosed with CRD were recruited between September 2014 and October 2014 for direct testing of the CERKL c.375C>G, and c.193G>T mutations by Sanger sequencing at the Laboratory of Genetics, HUSLAB, Helsinki.
The average age of the patients in the 55 RD patient cohort was 36 years ranging from seven to 71 years of age. Approximately half of the patients were men (27/55), and half women (28/55). Majority of the patients were of Finnish origin, and only three of 55 originated from other countries, namely Thailand, Iraq and Marocco. The mode of inheritance was classified according to family history and verified from medical records whenever possible. Most of the cases (31/55) were sporadic, whereas autosomal recessive inheritance was seen in twelve families, and autosomal dominant in six families. Only one of the families demonstrated a clear X-linked mode of inheritance. In five families, the mode of inheritance was unclear. To our knowledge, the patients were unrelated.
All 61 patients were examined at the Department of Ophthalmology including analysis of refraction, VA and fundus changes. Also, Goldman visual field testing, electroretinography (ERG), optical coherence tomography (OCT) and fundus autofluorescence imaging were performed. A three-generation pedigree was obtained from eight patients with CERKL mutations, including data on the birthplaces of the grandparents. When indicated, the DNA samples of the parents, siblings and grandparents of patients were also analysed.
The NGS-based gene panel analysis was performed as follows. Enrichment Sullivan et al. 2012) . The target enrichment design consists of the coding region of transcripts, including exon-intron junctions (AE5 bases), for 105 genes associated with RD which were identified through RetNet (https:// sph.uth.edu/retnet/) and OMIM. The samples were sequenced using a HiSeq 2500 (Illumina), according to manufacturer 0 s protocols. Sequenced reads from the HiSeq were aligned to the human reference sequence hg19 (build GRCh37) with the Burrows-Wheeler aligner (BWA v0.6 .2) (Li & Durbin 2009 ). The genome analysis tool kit (GATK v2.4.7) (McKenna et al. 2010) was used for base quality score recalibration and indel realignment prior to variant calling using the Unified Genotyper. Single nucleotide polymorphisms (SNPs) with ≥59 coverage and indels were annotated to genes using Ensembl v68, and the functional consequences were defined. Additional annotation was provided from OMIM and Genomic Evolutionary Rate Profiling (GERP) (35 species alignment) as well as population frequencies from 1000 genomes project (phase 1 release), NHLBI Exome Sequencing Project (v6500), in-house frequencies. PolyPhen-2, and Sorting Intolerant from Tolerant (SIFT) predictions were also included to help determine pathogenicity. A minimum of 97.6% of the overall target coding region of the transcripts was covered to a read depth of 509. All the mutations identified by NGS were confirmed by Sanger sequencing.
Results
The genetic aetiology was revealed in 60% (33/55) of the patients who were not known to be related (Table 1) . The most striking finding was that 22% (12/55) of the patients were found to carry two mutations in the autosomal recessive gene CERKL. At a later date, six additional patients, in whom direct mutation analysis for CERKL c.375C>G and c.193G>T was performed, were included in the study comprising a group of 18 patients in total with CERKL mutations. Of these, 56% (10/18) were homozygous for the CERKL c.375C>G p.(Cys125Trp) mutation (CERKL; NM_001030311.2). The parents of four of these patients were shown to be heterozygous carriers of the c. 375C>G mutation, confirming bi-allelic inheritance in the probands. Two patients were found to be homozygous for a CERKL nonsense mutation, c.193G>T p.(Glu65Ter), and four patients were compound heterozygotes for CERKL c.375C>G and CERKL c.193G>T p.(Glu65Ter). One patient was heterozygous for c. 375C>G and a missense change, CERKL c.316C>T p. (Arg106Cys), and the final patient was heterozygous for c. 375C>G and a nonsense mutation, CERKL c.847C>T p.(Arg283-Ter), on the second allele. The father of the latter patient originates from Spain (sample not available), where the CERKL c.847C>T p.(Arg283Ter) mutation has previously been reported (Tuson et al. 2004) , and his mother was shown to have the c.375C>G allele.
The average age of the CERKL cohort patients (18 patients) was 38 years ranging from 20 to 63 years of age. Eleven patients were female and seven male. All patients were of Finnish origin, and their family history was compatible with autosomal recessive mode of inheritance. The majority of the patients had juvenile unspecified macular dystrophy as their initial diagnosis, while two patients had Stargardt disease as the initial diagnosis, due to Stargardt-like phenotype. Patient 10 was reported earlier (Forsius et al. 1990 ) as an affected member of a family with autosomal recessive RCD.
The age of onset of the disease in the CERKL cohort (18 patients) varied from 7 to 38 years, the average age being 21 years of age. The ophthalmological findings of the CERKL patients are presented in detail in Table 2 . All 10 patients homozygous for the c.375C>G mutation in this study had an initial macular involvement with granular pigment in the macula, progressing to geographic atrophy (one patient) and to wide-spread generalized retinal atrophy in two patients. (29) Parafoveal thinning and granularity of RPE, outer retina Isoelectric (37) Central thinning of the outer retina and RPE Electroretinographys (ERGs) were usually taken when the patients were first referred to the Department of Ophthalmology. Of the total of 10 patients homozygous for c.375C>G, three had severely reduced rod ERG responses while the cone responses were normal or only slightly reduced, at ages 20, 28 and 39 years, two had isoelectric ERGs at 37 and 40 years, and three had both rod and cone responses equally diminished at 29, 35 and 62 years. Only one patient had initial cone dysfunction as judged from the ERG, at 20 years, one patient had normal corneal ERG at age 37 years.
Patients who were compound heterozygous for the c.375C>G and the c.193C>G mutations (4 patients) had mainly macular changes with VA ranging from 0.20 to 0.8 (age range 27-47 years); however, three of these patients showed an initial rod dysfunction based on ERG taken at early stages of the disease. In one of the patients, only multifocal ERG was performed, showing reduced central photopic responses. Two patients were homozygous for c.193C>G. The older patient (pt #10, 46 years) had a severe phenotype with severely reduced ERG, and VA of light perception/hand movement, while the younger patient (pt#5, 20 years) had predominantly macular changes, visual acuities of 0.5/0.63, normal Goldmann visual fields and diminished rod responses and subnormal cone responses in ERG. Patient 10 was described at 19 years with VA of 0.4 OU and pericentral visual field defects in Goldmann perimetry (Forsius et al. 1990 ). The patient heterozygous for the c.375C>G and the c.847C>T (Spanish) mutation was initially diagnosed as cone dystrophy at the age of 10. The disease eventually progressed to extensive retinal atrophy, and the patient's vision deteriorated to hand movement by the age of 47.
The mildest CERKL-related phenotype in our study was associated with compound heterozygosity of c.375C>G and c.316C>T with macular hypopigmentation, normal ERG and visual acuities of 1.0/0.8 at the age of 35.
Overall, in our cohort of 18 CERKL patients, most had a small central foveal island with relatively good VA, and a perifoveal retinal atrophy leading to pericentral scotomas. Patients with later stages of the disease had severely diminished visual acuities from 0.16 to hand movement and large central scotomas. The most severe phenotype was characterized by panretinal atrophy and VA of only light perception in both eyes in his 40s. Along with the initially reduced VA, problems in night vision were common among the first symptoms of the disease. Reduced rod and cone ERG responses were noted in early disease stages while rod responses were often more severely reduced than cone responses, in accordance with the early symptom of night blindness. One patient had negative ERG, and three patients who all had severe vision loss had isoelectric ERGs.
Patients with persisting macular function showed a characteristic macular OCT with parafoveal thinning of the outer retina and the RPE, suggesting this as the primary site of the disease (Fig. 1) . In autofluorescent images, the parafoveal ring was typically hyperautofluorescent, and the fovea showed granular or punctate hypoautofluorescence. In advanced disease, generalized punctate and large round hypoautofluorescent lesions were seen throughout the fundus (Fig. 1) .
To examine the geographical origin of the CERKL mutation, the birthplaces of the grandparents of eight CERKL patients were located on the map of Finland. The results show that there is a tendency towards clustering of birthplaces to Savo and Karelia regions located in eastern parts of Finland (Fig. 2) .
Recurrent mutations in other genes were also identified in this study. Three patients of the cohort were found to be homozygous for a nonsense mutation, c.1155T>A p.(Cys385Ter), in the EYS gene. Interestingly, this mutation occurs in cis with an 8-bp deletion (c.8648_8655del8) downstream forming an obvious founder haplotype. Two patients were homozygous for RP1 c.515T>G p.(Leu172Arg), and one individual was compound heterozygote for RP1 c.515T>G p. (Leu172Arg) and RP1 c.121T>C p.(Tyr41His). ABCA4 variants c. 1622T>C p. (Leu541Pro), and c.3113C>T p.(Ala1038Val) have previously been reported to occur together 'in cis' as a complex allele (Wiszniewski et al. 2006) in RD patients, and we found this complex allele in two patients in conjunction with separate mutations in trans. The phenotypes of these patients were compatible with typical Stargardt (in conjunction with c.1610G>A p. (Arg537His)), and lateonset Stargardt (in conjunction with c.1993G>T). The allele frequencies of the recurrent missense and nonsense mutations in Finnish and non-Finnish European populations are presented in Table 3 .
We also detected a homozygous GUCY2D mutation, c.2944+1delG, in two patients. The phenotypes of both patients were compatible with Leber congenital amaurosis (LCA).
The remaining mutations detected in the study were seen only once (PRPH2, RHO, CLRN1, PRPF8, RP2). Two heterozygous mutations associated with dominant RP, c.541G>A p.(Glu181Lys) in rhodopsin (RHO) and c.6470T>A p.(Val2157Glu) in PRPF8 were detected in two families, each with several affected individuals. These mutations were shown to segregate with autosomal dominant retinitis pigmentosa (ADRP) in the respective families (Fig. 3) . A hemizygous mutation c.969+3A>G in the X-linked gene RP2 was identified in one male RP patient. His brother also had RP, and his mother and sister were mildly affected; however, DNA samples were not available for testing. The patient who was found compound heterozygous for two CLRN1 mutations (Fin major and Fin minor) did not have hearing loss at the age of 15 when he was diagnosed with RP; thus, he was not suspected to have Usher syndrome type 3, the most common Usher syndrome type in Finland. Mild and possibly late-onset hearing loss has earlier been suggested to be associated with compound heterozygosity of the Finnish major and minor mutations (Plantinga et al. 2005) .
In addition likely pathogenic mutations were identified in RP2, BEST1, TULP1 and MERTK genes. The mutation in RP2 segregated with the phenotype in the family. The likely pathogenic mutations were shown to occur in BEST1, TULP1 and MERTK in trans.
Discussion
CERKL was first recognized to be associated with RD by a Spanish group. They identified CERKL c.847C>T p. (Arg283Ter) (NM_001030311.2) mutations (reported as c.769C>T, p.(Arg257Ter) in NM_201548.4), in two consanguineous Spanish RP families (Tuson et al. 2004 ). Subsequently, the c.847C>T mutation was found to account for 4.8% (9/186) of typical RP cases in Spain (Avila-Fernandez et al. 2010) . In all cases, the mutation was found in homozygous state and was absent in 340 normal control chromosomes. To date, sixteen CERKL mutations in total have been reported in patients with retinal dystrophy, including the ones in this study. These are listed in Table 4 .
The CERKL gene encodes the Ceramide Kinase-Like (CERKL) protein which has many isoforms. CERKLa is the full-length protein, which is conserved in vertebrates and comprises 13 exons and 532 amino acids (Fathinajafabadi et al. 2014) . CERKL is abundant in cone cells and also present in rod cells and at the inner nuclear layer and ganglion cell layer of the retina (Mandal et al. 2013) . It belongs to the ceramide kinase (CERK) protein family, whose members share a Pleckstrin homology (PH) domain and an evolutionary conserved diacylglyserol kinase domain involved in sphingolipid metabolism (Bornancin et al. 2005) . Overexpression of CERKL has been shown to protect cells from apoptosisinduced oxidative stress, and the dynamic localization of CERKL suggests multiple sites of action (Tuson et al. 2004) . Recently, the cellular role of CERKL has been studied (Fathinajafabadi et al. 2014) , CERKLa was identified to be a main component of compact and untranslated messenger ribonucleoprotein particles (mRNPs), which associates with other RNP complexes such as stress granules, P-bodies and polyribosomes. CERKLa was found to bind through its N-terminus to mRNAs and interact with other mRNA-binding proteins such as elF3B, PABP, HSP and RPS3.
CERKL has been shown to be important in the pathogenesis of retinal dystrophy as Cerkl knockdown in zebrafish causes retinal degeneration (Riera et al. 2013) , and a decrease in sphingolipid content is seen in the Cerkl knockdown mouse retinas (Garanto et al. 2012) , whereas Cerkl À/À mice have no retinal degeneration phenotype (Graf et al. 2008 ).
Many studies show that CERKL is one of the many minor genes involved in autosomal recessive CRD/RP, typically accounting around 2-4% of the patients with autosomal recessive RD (Littink et al. 2010; Abu-Safieh et al. 2013; Fu et al. 2013; Nishiguchi et al. 2013; Glockle et al. 2014 ). An interesting exception is the Yemenite Jewish population of approximately 174, 600 people where a homozygous CERKL splice site mutation c.238+1G>A was shown to underlie approximately 33% of autosomal recessive retinal degeneration (Auslender et al. 2007 ). The carrier frequency of the mutation was reported to be as high as 4.4%.
We have shown that in Finland with a population of 5.5 million people, mutation of the CERKL gene is a major cause of RD. The most frequent mutation, c.375C>G p. (Cys125Trp), accounts for 72% (26/36) of the CERKL mutations in Finland. The allele frequency of c.375C>G in the Finnish population is 0.00763 (ExAC). However, the allele frequency in the European non-Finnish population is as low as 0.00019 (ExAC Browser) showing that this allele is truly enriched in the Finnish population. Recently, the pathogenicity of CERKL c.375G>C has been functionally proven. The mutation impairs normal trafficking of the CERKL protein into the nucleus and affects normal binding to the mRNA-binding protein, elF3b, resulting in the failure to form mRNP complexes (Fathinajafabadi et al. 2014) .
Two novel CERKL mutations were found in this study. CERKL c.193G>T p.(Glu65Ter) is predicted to disrupt normal translation of the CERKL and is therefore considered pathogenic. CERKL c.316C>T p.(Arg106Cys) has not been reported previously in the literature nor has it been reported as a polymorphism. However, a different amino acid substitution at the same codon p.(Arg106Ser), located within the conserved nuclear localization signal sequence (KLKRR) of the CERKL protein, has been shown to segregate with disease in a family with retinal degeneration (Ali et al. 2008) . Furthermore, in silico analysis using AlignGVGD, SIFT and Polyphen-2 suggests that c.316C>T has a detrimental effect on the CERKL protein, although this has not been functionally proven.
The finding of several founder mutations in RD reported in Table 3 , and Fu et al. (2013) c.2944+1delG in GUCY2D (Hanein et al. 2002) (Table 1) is consistent with the population history of the Finns. Due to the small number of founders, isolation and population bottle-necks several rare genetic disorders are enriched in the Finnish population constituting the Finnish Disease Heritage (Norio 2003) . When mutation frequencies in certain regions are compared to the overall population frequency, strong geographical clustering of founder mutations within the country is often found. Also, founder mutations in various more common phenotypes such as familial hypercholesterolemia and cardiomyopathy (Jaaskelainen et al. 2014; Lahtinen et al. 2015) have been reported in Finnish population. The number of known CERKL-associated RP patients has been limited due the rarity of the disease. Previously, CERKL mutations have been shown to be associated with an autosomal recessive cone-rod dystrophy, prominent maculopathy, variable VA and pigmentary deposits, leading to a deficit in both peripheral and central vision (Ali et al. 2008; Aleman et al. 2009; Littink et al. 2010 ). We present one of the largest patient cohort reported to date, adding to the understanding of the range of phenotypes associated with CERKL mutations. The range of phenotypes of our patients varied from mild to moderate macular-onset disease with subtle to moderate loss of vision, night blindness and pericentral relative or absolute scotomas to wide-spread retinal dystrophy with severe visual handicap.
Finally, our report indicates that the first diagnostic test for Finnish patients with sporadic or autosomal recessive retinal disease should be a targeted test for founder mutations in the CERKL, EYS, RP1, ABCA4 and GUCY2D genes. Furthermore, these results confirm the utility of NGS-based gene panels as a powerful method for mutation identification in RD, thus enabling improved genetic counselling for these families.
